Eltropag 50 mg (Tablet)

Unit Price: ৳ 900.00 (1 x 10: ৳ 9,000.00)
Strip Price: ৳ 9,000.00

Medicine Details

Category Details
Generic Eltrombopag olamine
Company Incepta pharmaceuticals ltd
Also available as
Eltropag 25 mg tablet

Product Title

  • Eltrombopag Olamine

Categories

  • Medicine
  • Thrombopoietin (TPO) Receptor Agonist

Description

  • Eltrombopag Olamine is a small molecule thrombopoietin (TPO) receptor agonist. It is indicated for the treatment of thrombocytopenia in patients with persistent or chronic immune thrombocytopenia, hepatitis C infection, and severe aplastic anemia.

Indications

  • Treatment of thrombocytopenia in patients with persistent or chronic immune thrombocytopenia
  • Treatment of thrombocytopenia in patients with hepatitis C infection
  • Treatment of severe aplastic anemia

Mode of Action

  • Interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades that induce proliferation and differentiation from bone marrow progenitor cells, leading to increased platelet production

Dosage and Administration

  • Oral route of administration
  • Use lowest dose to achieve and maintain a platelet count greater than or equal to 50x10^9/L
  • Different dosage for adult and pediatric patients with ITP, chronic hepatitis C associated thrombocytopenia, first line severe aplastic anemia, and refractory severe aplastic anemia

Drug Interaction

  • Take eltrombopag at least 2 hours before or 4 hours after any medications or products containing polyvalent cations such as antacids and mineral supplements

Contraindications

  • Known hypersensitivity to eltrombopag or any components of this product

Side Effects

  • Anemia
  • Nausea
  • Pyrexia
  • ALT increased
  • Cough
  • Fatigue
  • Headache
  • Diarrhea

Pregnancy and Lactation

  • No sufficient data available for assessing risks on major birth defects, miscarriage, or adverse maternal or fetal outcomes
  • Breastfeeding not recommended during treatment

Precautions and Warnings

  • Increased risk of hepatic decompensation in patients with chronic hepatitis C
  • Increased risk of death and progression of myelodysplastic syndromes to acute myeloid leukemia
  • Portal vein thrombosis reported in patients with chronic liver disease receiving eltrombopag

Use in Special Populations

  • Safety and efficacy not established in pediatric patients below the age of 1 year with ITP, thrombocytopenia associated with chronic hepatitis C, and refractory severe aplastic anemia

Overdose Effects

  • Platelet counts may increase excessively and result in thrombotic or thromboembolic complications
  • Consider oral administration of a metal cation-containing preparation in case of overdose

Therapeutic Class

  • Haemostatic drugs

Storage Conditions

  • Store in a cool (below 25°C) and dry place protected from light
  • Keep away from the reach of children

Related Brands